ARS-2102

ARS-2102 is a potent, covalent inhibitor of KRAS G12C, an oncogenic mutant form of the KRAS protein. It is designed for use in cancer research and functions by irreversibly binding to the cysteine residue at position 12 (G12C) of the KRAS protein, thereby inhibiting its activity. This mechanism targets cancers driven by the KRAS G12C mutation, which is commonly found in certain types of non-small cell lung cancer and other solid tumors. ARS-2102 represents a first-generation covalent inhibitor with an atropisomeric biaryl scaffold, developed through advanced synthetic chemistry techniques to achieve high selectivity and potency against mutant KRAS G12C[1][3][7].